Metabolism and urinary excretion kinetics of di(2-ethylhexyl) adipate (DEHA) in four human volunteers after a single oral dose
- PMID: 31816331
- DOI: 10.1016/j.toxlet.2019.12.006
Metabolism and urinary excretion kinetics of di(2-ethylhexyl) adipate (DEHA) in four human volunteers after a single oral dose
Abstract
Di(2-ethylhexyl) adipate (DEHA) is used as a substitute for the reprotoxic phthalate plasticizer di(2-ethylhexyl) phthalate (DEHP). This study reports the first quantitative data on human in vivo DEHA metabolism and urinary metabolite excretion with the aim of providing tools for DEHA exposure and risk assessments. After DEHA was administered to four healthy volunteers (107-164 μg/kg body weight (bw)), urine samples were continuously and completely collected for 48 h and analyzed for the specific oxidized monoester metabolites mono-2-ethyl-5-hydroxyhexyl adipate (5OH-MEHA), mono-2-ethyl-5-oxohexyl adipate (5oxo-MEHA), and mono-5-carboxy-2-ethylpentyl adipate (5cx-MEPA), as well as for the non-specific hydrolysis product adipic acid (AA) using stable isotope dilution analysis. AA was confirmed as a major (urinary excretion fraction (FUE): 10-40%), yet non-specific DEHA metabolite. 5cx-MEPA was the major specific DEHA metabolite with an FUE of 0.20% (range: 0.17-0.24%). FUEs for 5OH-MEHA and 5oxo-MEHA were 0.07% (0.03-0.10%) and 0.05% (0.01-0.06%), respectively. The three specific metabolites were excreted with two concentration maxima (tmax1 = 1.5-2.3 h, tmax2 = 3.8-6.4 h). Elimination half-lives (t1/2, calculated after the second tmax) for 5cx-MEPA were calculated between 2.1-3.8 h. The majority (98-100%) of metabolites was excreted within 24 h. The FUE of 5cx-MEPA was applied to demonstrate its applicability for calculating daily intakes based on urinary metabolite levels from three pilot populations. Daily intakes were generally far below the tolerable daily intake (TDI) for DEHA (300 μg/kg bw/day). The highest daily intake (114 μg/kg bw/day) was calculated in individuals after consuming food that had been wrapped in DEHA containing cling film.
Keywords: DEHA; Di(2-ethylhexyl) adipate; Human biomonitoring; Metabolism; Oral dose; Plasticizer.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Mar 23;14:1165770. doi: 10.3389/fphar.2023.1165770. eCollection 2023. Front Pharmacol. 2023. PMID: 37033641 Free PMC article.
-
Determination of human urinary metabolites of the plasticizer di(2-ethylhexyl) adipate (DEHA) by online-SPE-HPLC-MS/MS.J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:239-246. doi: 10.1016/j.jchromb.2019.06.019. Epub 2019 Jun 17. J Chromatogr B Analyt Technol Biomed Life Sci. 2019. PMID: 31233945
-
Human metabolism and urinary excretion kinetics of di-n-butyl adipate (DnBA) after oral and dermal administration in three volunteers.Toxicol Lett. 2021 Jun 1;343:11-20. doi: 10.1016/j.toxlet.2021.02.012. Epub 2021 Feb 25. Toxicol Lett. 2021. PMID: 33640488 Clinical Trial.
-
Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure-- an update and latest results.Int J Androl. 2006 Feb;29(1):155-65; discussion 181-5. doi: 10.1111/j.1365-2605.2005.00607.x. Int J Androl. 2006. PMID: 16466535 Review.
-
Di(2-ethylhexyl) adipate.IARC Monogr Eval Carcinog Risks Hum. 2000;77:149-75. IARC Monogr Eval Carcinog Risks Hum. 2000. PMID: 11100400 Free PMC article. Review. No abstract available.
Cited by
-
Stoffmonographie für Diethylhexyladipat (Di(2-ethylhexyl)adipat, DEHA) – HBM-I-Werte für den Metaboliten Mono-5-carboxy-(2-ethylpentyl)adipat (5cx-MEPA) im Urin von Erwachsenen und Kindern : Stellungnahme der Kommission „Human-Biomonitoring“ des Umweltbundesamtes.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023 Jun;66(6):702-712. doi: 10.1007/s00103-023-03715-2. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023. PMID: 37306729 German. No abstract available.
-
Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Mar 23;14:1165770. doi: 10.3389/fphar.2023.1165770. eCollection 2023. Front Pharmacol. 2023. PMID: 37033641 Free PMC article.
-
Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Feb 20;14:1140852. doi: 10.3389/fphar.2023.1140852. eCollection 2023. Front Pharmacol. 2023. PMID: 36891271 Free PMC article.
-
Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Feb 2;14:1111433. doi: 10.3389/fphar.2023.1111433. eCollection 2023. Front Pharmacol. 2023. PMID: 36865923 Free PMC article.
-
Development, Testing, Parameterisation and Calibration of a Human PBPK Model for the Plasticiser, Di-(2-propylheptyl) Phthalate (DPHP) Using in Silico, in vitro and Human Biomonitoring Data.Front Pharmacol. 2021 Sep 2;12:692442. doi: 10.3389/fphar.2021.692442. eCollection 2021. Front Pharmacol. 2021. PMID: 34539393 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
